Strategies for Delivering Peptide Drugs Across the Blood-Brain Barrier
Receptor-mediated transcytosis using cell-penetrating peptides, targeting peptides, or antibodies enables drug delivery across the blood-brain barrier for treating CNS diseases.
Quick Facts
What This Study Found
RMT strategies using CPPs, targeting peptides, or antibodies that bind TfR, LDLR, or InsR on brain endothelial cells can overcome the BBB and deliver therapeutics to the brain.
Key Numbers
3 key receptors (TfR, LDLR, InsR); 3 ligand types; several clinical candidates
How They Did This
Narrative review of RMT mechanisms, targeting ligand types, receptor biology, and clinical development status of BBB-crossing drug conjugates.
Why This Research Matters
The blood-brain barrier blocks most drugs from reaching the brain, limiting treatment options for Alzheimer's, Parkinson's, and other neurological diseases. RMT-based delivery could unlock therapies currently unable to reach their targets.
The Bigger Picture
Solving the BBB delivery problem is one of the biggest challenges in neurological drug development. Peptide-based targeting strategies are among the most promising approaches.
What This Study Doesn't Tell Us
Review article. Many strategies are preclinical. Achieving sufficient brain concentrations while avoiding peripheral effects remains challenging.
Questions This Raises
- ?Which receptor target provides the best brain penetration?
- ?Can peptide-based BBB delivery achieve therapeutic drug concentrations?
- ?How do targeting efficiency and specificity compare between CPPs and mAbs?
Trust & Context
- Key Stat:
- 3 receptor targets Transferrin, LDL, and insulin receptors on brain endothelial cells used for receptor-mediated drug transport across the BBB
- Evidence Grade:
- Review of preclinical and clinical delivery strategies. Provides a comprehensive framework but most approaches are still in development.
- Study Age:
- Published in 2020. BBB delivery research has continued to advance with new clinical candidates.
- Original Title:
- Smart Strategies for Therapeutic Agent Delivery into Brain across the Blood-Brain Barrier Using Receptor-Mediated Transcytosis.
- Published In:
- Chemical & pharmaceutical bulletin, 68(4), 316-325 (2020)
- Authors:
- Tashima, Toshihiko
- Database ID:
- RPEP-05160
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
What is the blood-brain barrier and why is it a problem?
The BBB is a tight layer of cells lining brain blood vessels that blocks most drugs from entering the brain. While it protects the brain from toxins, it also prevents potentially life-saving medications from reaching brain targets in diseases like Alzheimer's.
How do peptides help drugs cross the BBB?
Peptides can be attached to drugs as targeting ligands. These peptides bind to specific receptors on BBB cells, triggering a transport process called transcytosis that carries the drug-peptide conjugate across the barrier and into the brain.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05160APA
Tashima, Toshihiko. (2020). Smart Strategies for Therapeutic Agent Delivery into Brain across the Blood-Brain Barrier Using Receptor-Mediated Transcytosis.. Chemical & pharmaceutical bulletin, 68(4), 316-325. https://doi.org/10.1248/cpb.c19-00854
MLA
Tashima, Toshihiko. "Smart Strategies for Therapeutic Agent Delivery into Brain across the Blood-Brain Barrier Using Receptor-Mediated Transcytosis.." Chemical & pharmaceutical bulletin, 2020. https://doi.org/10.1248/cpb.c19-00854
RethinkPeptides
RethinkPeptides Research Database. "Smart Strategies for Therapeutic Agent Delivery into Brain a..." RPEP-05160. Retrieved from https://rethinkpeptides.com/research/tashima-2020-smart-strategies-for-therapeutic
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.